Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Ontario Clinical Oncology Group (OCOG) Ortho Biotech Products, L.P. |
---|---|
Information provided by: | Ontario Clinical Oncology Group (OCOG) |
ClinicalTrials.gov Identifier: | NCT00310232 |
The general objective of this study is to improve the Quality of Life (QoL) of selected patients with advanced carcinoma of the lung. The specific objective is to evaluate the effect of treatment with epoetin alfa (recombinant human erythropoietin) on anemia related QoL and anemia in non-small cell lung cancer patients with advanced stage disease and underlying anemia of malignancy.
Condition | Intervention | Phase |
---|---|---|
Non-Small-Cell Lung Carcinoma Lung Cancer Anemia |
Drug: Epoetin Alfa |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Randomized Trial of Epoetin Alfa in Patients With Advanced Non-Small Cell Carcinoma of the Lung (EPO-CAN-20) |
Enrollment: | 70 |
Study Start Date: | February 2001 |
Study Completion Date: | April 2004 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Canada, Alberta | |
Cross Cancer Institute | |
Edmonton, Alberta, Canada, T6G 1Z2 | |
Tom Baker Cancer Centre | |
Calgary, Alberta, Canada, T2N 4N2 | |
Canada, Manitoba | |
Cancer Care Manitoba | |
Winnipeg, Manitoba, Canada, R3E 0V9 | |
Canada, New Brunswick | |
St. John Regional Hospital | |
St. John, New Brunswick, Canada, E2L 4L2 | |
Canada, Newfoundland and Labrador | |
Newfoundland Cancer Treatment & Research Foundation | |
St. John's, Newfoundland and Labrador, Canada, A1B 3V6 | |
Canada, Nova Scotia | |
Nova Scotia Cancer Centre | |
Halifax, Nova Scotia, Canada, B3H 1V7 | |
Canada, Ontario | |
Hamilton Regional Cancer Centre (Juravinski) | |
Hamilton, Ontario, Canada, L8V 5C2 | |
Princess Margaret Hospital | |
Toronto, Ontario, Canada, M5G 2M9 | |
Hotel Dieu Hospital | |
St. Catherines, Ontario, Canada, L2K 5K3 | |
Northeastern Ontario Regional Cancer Centre | |
Sudbury, Ontario, Canada, P3E 5J1 | |
Toronto East General Hospital | |
Toronto, Ontario, Canada, M4C 3E7 | |
Windsor Regional Cancer Centre | |
Windsor, Ontario, Canada, N8W 2X3 | |
Toronto Sunnybrook Regional Cancer Centre | |
Toronto, Ontario, Canada, M4N 3M5 | |
London Regional Cancer Centre | |
London, Ontario, Canada, N6A 4L6 | |
Canada, Quebec | |
McGill University Clinical Trials Operations | |
Montreal, Quebec, Canada, H2W 1S6 |
Study Chair: | Jim Wright, MD | Hamilton Regional Cancer Centre |
Study Director: | Mark Levine, MD | Ontarion Clinical Oncology Group |
Study ID Numbers: | CTA-Control-076080, HC File 9427-J0921-22C |
Study First Received: | March 31, 2006 |
Last Updated: | June 29, 2007 |
ClinicalTrials.gov Identifier: | NCT00310232 History of Changes |
Health Authority: | Canada: Health Canada |
Quality of Life Blood transfusion |
Epoetin Alfa Thoracic Neoplasms Respiratory Tract Diseases Hematinics Lung Neoplasms Lung Diseases |
Anemia Non-small Cell Lung Cancer Quality of Life Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |
Thoracic Neoplasms Epoetin Alfa Respiratory Tract Neoplasms Neoplasms by Histologic Type Hematinics Hematologic Agents Pharmacologic Actions Carcinoma |
Neoplasms Neoplasms by Site Respiratory Tract Diseases Lung Neoplasms Therapeutic Uses Lung Diseases Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial |